跳至主要内容
临床试验/ISRCTN10166784
ISRCTN10166784已完成未知

A randomised controlled multi-centre open-label parallel-group non-inferiority trial of the clinical effectiveness, acceptability and cost-effectiveness of a ‘stepping into day treatment’ approach versus inpatient treatment as usual for anorexia nervosa in adult specialist eating disorder services

King's College London0 个研究点目标入组 15 人开始时间: 2020年2月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
15

研究概览

简要总结

2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35710394/ (added 17/06/2022) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36952308/ (added 20/02/2024) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/38109218/ (added 20/02/2024)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 04/09/2020:
  • 1. Adults aged 17 years and above
  • 2. Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of severe anorexia nervosa (AN) or related disorder (e.g., avoidant/restrictive food intake disorder [ARFID; where food restriction and weight loss occur in the absence of concerns about shape and weight])
  • 3. Body mass index (BMI) equal to or less than 16 kg/m²
  • 4. In need for intensive treatment because of either rapid weight loss, and/or evidence of system/organ failure/medical instability and/or unsuccessful outpatient treatment
  • 5. Have mental capacity to give informed consent to participate in the study
  • Previous inclusion criteria:
  • 1. Male and female adults
  • 2. Aged 17 years and above
  • 3. Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of severe anorexia nervosa (AN) or related disorder (e.g., avoidant/restrictive food intake disorder [ARFID; where food restriction and weight loss occur in the absence of concerns about shape and weight])
  • 4. Body mass index (BMI) of less than 16 kg/m²
  • 5. In need for intensive treatment because of either rapid weight loss, and/or evidence of system/organ failure/medical instability and/or unsuccessful outpatient treatment
  • 6. Have mental capacity to give informed consent to participate in the study

排除标准

  • Current exclusion criteria as of 04/09/2020:
  • 1. Insufficient knowledge of English to complete study assessments or understand treatment
  • 2. Severe learning disability
  • 3. Severe medical or psychiatric (co)morbidity (e.g. psychosis, substance dependence) needing treatment in its own right
  • 4. Those living too far away from day-patient treatment (and where no alternative arrangements for regular attendance at day-patient treatment can be made).
  • Previous exclusion criteria:
  • 1. Insufficient knowledge of English to complete study assessments or understand treatment
  • 2. Severe learning disability
  • 3. Severe medical or psychiatric (co)morbidity (e.g. psychosis, substance dependence) needing treatment in its own right
  • 4. Those living too far away from day-patient treatment (and where no alternative arrangements for regular attendance at day-patient treatment can be made).
  • 5. Those who are involved in current research or have recently been involved in any research prior to recruitment

研究者

相似试验

已完成
3 期
An open-label, multicenter, randomized, controlled adaptive study to evaluate the efficacy and safety of investigational therapeutics for the treatment of hospitalized patients with mild to moderate novel coronavirus disease (COVID-19) in Kinshasa, Democratic Republic of the Congo
ISRCTN16254682Creppat Laboratories SAR376
已完成
不适用
A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating productCigarette smokingMental and Behavioural DisordersMental and behavioural disorders due to use of tobacco
ISRCTN14301360British American Tobacco (Investments) Ltd180
进行中(未招募)
2 期
Stopping Eculizumab Treatment Safely in atypical Haemolytic Uraemic Syndrome (SETS aHUS)Atypical hemolytic uremic syndromeUrological and Genital DiseasesHaemolytic-uraemic syndrome
ISRCTN17503205The Newcastle Upon Tyne Hospitals NHS Foundation Trust39
已完成
2 期
The Cardiac CARE Trial – can heart muscle injury related to chemotherapy be prevented?Heart muscle injury in patients receiving chemotherapy for breast cancer or non-Hodgkin lymphomaCirculatory System
ISRCTN24439460ACCORD - University of Edinburgh & NHS Lothian co-sponsors168
已完成
2 期
A Phase II, Open Label, Multicenter Randomised Controlled Trial Comparing Hyperthermia Plus Mitomycin To Mitomycin Alone, In Patients with Intermediate Risk Non-Muscle Invasive Bladder CancerTopic: CancerSubtopic: Bladder CancerDisease: Bladder (advanced), Bladder (superficial)Bladder, unspecifiedCancer
ISRCTN23639415Queen Mary University of London (UK)259
Comparing the clinical effectiveness, acceptability... | 临床试验